Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus deucravacitinib in adults with moderate plaque psoriasis
NL-OMON60380Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of risankizumab and deucravacitinib in plaque psoriasis (4 arms), sponsored by AbbVie Inc. Primary endpoints: Achievement of PASI 90 at Week 16, Achievement of sPGA 0 or 1 with at least 2-grade improvement at Week 16 and 1 more. Started Jul 2024; status: completed.
02
Drugs
risankizumabdeucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON60380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60380.